Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronicPseudomonas aeruginosainfection in cystic fibrosis

Levofloxacin Inhalation Solution (MP-376) in Patients with Cystic Fibrosis withPseudomonas aeruginosa

(2011) David E. Geller et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Pharmacokinetics and Safety of MP-376 (Levofloxacin Inhalation Solution) in Cystic Fibrosis Subjects

(2011) David E. Geller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PulmoSphere™ Technology

(2011) David E. Geller et al.   Journal of Aerosol Medicine and Pulmonary Drug Delivery

107 In vitro susceptibility of Pseudomonas aeruginosa (PA) does not predict clinical response to aztreonam 75 mg powder and solvent for nebuliser solution (AZLI): a responder analysis in subjects with cystic fibrosis (CF)

(2011) T. Pressler et al.   Journal of Cystic Fibrosis

Outpatient Treatment ofPseudomonas aeruginosaBronchial Colonization with Long-term Inhaled Colistin, Tobramycin, or Both in Adults without Cystic Fibrosis

(2011) David Berlana et al.   PHARMACOTHERAPY

Adherence with tobramycin inhaled solution and health care utilization

(2011) Becky A Briesacher et al.   BMC Pulmonary Medicine

Efficiency of the inhalational tobramycin therapy in complex antibacterial therapy of lung exacerbation in cystic fibrosis children with chronic Pseudomonas aeruginosa infection

(2010) S.Y. Semykin et al.   Journal of Cystic Fibrosis

Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial

(2010) Michael W. Konstan et al.   Journal of Cystic Fibrosis

Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE trial

(2010) Michael W. Konstan et al.   PEDIATRIC PULMONOLOGY

Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis

(2010) Eric J. Dziuban et al.   PEDIATRIC PULMONOLOGY

An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis

(2010) Christopher M. Oermann et al.   PEDIATRIC PULMONOLOGY

Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment

(2010) Giuseppe Valenza et al.   SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES

Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis

(2010) Michael D Parkins et al.   Expert Review of Respiratory Medicine

The Detrimental Health Effects of Traffic-related Air Pollution

(2009) Tim S. Nawrot et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Update in Cystic Fibrosis 2008

(2009) Felix Ratjen   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Cystic Fibrosis Pulmonary Guidelines

(2009) Patrick A. Flume et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Efficacy of Aerosol MP-376, a Levofloxacin Inhalation Solution, in Models of Mouse Lung Infection Due to Pseudomonas aeruginosa

(2009) M. Sabet et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Respiratory Microbiology of Patients With Cystic Fibrosis in the United States, 1995 to 2005

(2009) Samiya Razvi et al.   CHEST

Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis

(2009) George Z. Retsch-Bogart et al.   CHEST

Changes in Performance of the Pari eFlow® Rapid and Pari LC Plus™ during 6 Months Use by CF Patients

(2009) Bart L. Rottier et al.   Journal of Aerosol Medicine and Pulmonary Drug Delivery

Inhalation Equipment Hygiene: A Belgian National Survey

(2009) Gregory Reychler et al.   Journal of Aerosol Medicine and Pulmonary Drug Delivery

Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis

(2009) D. L. MacLeod et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Patient-reported respiratory symptoms in cystic fibrosis

(2009) C.H. Goss et al.   Journal of Cystic Fibrosis

Inhalable Antibiotic Delivery Using a Dry Powder Co-delivering Recombinant Deoxyribonuclease and Ciprofloxacin for Treatment of Cystic Fibrosis

(2009) Yan Yang et al.   PHARMACEUTICAL RESEARCH

Aerosol Antibiotics in Cystic Fibrosis

(2009) David E Geller   Respiratory Care

A Pipeline of Therapies for Cystic Fibrosis

(2009) Melissa Ashlock et al.   SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE

Aminoglycoside ototoxicity susceptibility in cystic fibrosis

(2009) S A Mulrennan et al.   THORAX

Inhaled Aztreonam Lysine for Chronic AirwayPseudomonas aeruginosain Cystic Fibrosis

(2008) Karen S. McCoy et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Effects of Antibiotics on Quorum Sensing in Pseudomonas aeruginosa

(2008) M. E. Skindersoe et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients

(2008) S. Islam et al.   CLINICAL MICROBIOLOGY AND INFECTION

In Vitro Analysis of Tobramycin-Treated Pseudomonas aeruginosa Biofilms on Cystic Fibrosis-Derived Airway Epithelial Cells

(2008) G. G. Anderson et al.   INFECTION AND IMMUNITY

Treatment compliance in children and adults with Cystic Fibrosis

(2008) Rosa Patricia Arias Llorente et al.   Journal of Cystic Fibrosis

High treatment burden in adults with cystic fibrosis: Challenges to disease self-management

(2008) Gregory S. Sawicki et al.   Journal of Cystic Fibrosis

Shifting patterns of inhaled antibiotic use in cystic fibrosis

(2008) Samuel M. Moskowitz et al.   PEDIATRIC PULMONOLOGY